Clinical Trials Logo

Clinical Trial Summary

Easing the morbidity and economic burden of age-related diseases is one of the major medical challenges. One of the key obstacles to healthy ageing is immune senescence, including the failure of lymphocytes to respond adequately to infection, malignancy and vaccination. Infectious diseases remain the fourth most common cause of death among the elderly in the developed world. Moreover, the gain of chronic low-grade non-specific inflammation with age contributes to many age-related diseases. Our early work showed that autophagy, the main cellular bulk degradation pathway in the cell, prevents ageing of the immune system. In preclinical models we showed an age-related decline in T cell autophagy. We rejuvenated the immune system by restoring autophagy in T and B cells with the autophagy-inducing metabolite spermidine. Here we are asking for matched funds for a small human clinical trial to confirm that spermidine has the same effect when administered to humans. We will give the nutraceutical spermidine to human volunteers aged >65 years either during or after vaccination against SARS-CoV-2 or influenza to test improvement of vaccine responses, immune senescence and inflamm-aging. We will also confirm whether a novel pathway we discovered that links spermidine to autophagy operates in humans, allowing us to make more specific drugs in the future. This small study of 120 volunteers overall will pave the way for a larger clinical trial with spermidine or novel related drugs.

Clinical Trial Description

The outbreak of SARS-CoV-2 and coronavirus disease (COVID-19) has caused a great threat to global public health with the majority of deaths occurring in older adults. The development of effective treatments and vaccines against COVID-19 has become a pressing and urgent challenge to overcome. Successful protective immune responses stimulated by vaccination of older people (people aged greater than 65 years old) against pathogens is considered one of the big challenges in our society (Weinberger, 2018; Chen et al., 2009). Immune senescence is thought to be important in the reduced immune response that has been widely observed, following immunization of older adults. This is characterized by poor induction and recall of B and T cell memory responses upon exposure to viruses and vaccines. Most vaccines are less immunogenic effective in the older population, in particular influenza vaccines (Weinberger, 2018). Autophagy is thought to be one of the few cellular processes that underlie many facets of cellular aging including immune senescence (Zhang et al., 2016). Autophagy delivers 'unwanted' cytoplasmic material to lysosomes inside a cell for degradation. Autophagy also limits mitochondrial dysfunction and accumulation of reactive oxygen species (ROS) (Rubinsztein et al., 2011). Deletion of key autophagy genes leads to a change in cellular immunity, with loss of function in mouse memory CD8+ T cells (Xu et al., 2014; Puleston et al., 2014), hematopoietic stem cells (Mortensen et al., 2011), and macrophages (Stranks et al., 2015). We have seen that autophagy levels also decline with age in human peripheral CD8+ T cells (Phadwal et al., 2012) and correlate with vaccine responses. Importantly, we have demonstrated that we can improve CD8+ T memory responses in aged mice with a supplement called spermidine (Puleston et al., 2014). Spermidine is a metabolite synthesised from arginine. It is commonly found in wheatgerm and soya and is available in the UK as a nutritional food supplement, often described as a polyamine. It's safety and tolerability has been studied and no adverse effects have been demonstrated (Schwarz et al.; 2018) and it is readily available to buy from mainstream retail companies e.g. Amazon. Our data showed for the first time that autophagy is indeed highly active in human CD8+ T cells in two different experimental vaccination trials (Alsaleh et al, eLife 2020). Polyamine levels also fall with age in peripheral mononuclear cells. When supplemented with spermidine, the autophagic function can be rejuvenated in CD8+ T cells from old donors, and levels of the important effector molecules increased. As a consequence, the immune response is enhanced. Moreover, autophagy and effector function are maintained by spermidine in T cells from young donors (Alsaleh et al, eLife 2020). This demonstrates that the function of human CD8+ T cells can be improved with spermidine. Taken together with our previous work on B cells (Zhang et al, Mol Cell 2019), this leads us to the hypothesis that both T and B cell responses to infections and vaccinations are exquisitely reliant on sufficient autophagy levels, which are maintained by intracellular spermidine. This work highlights the potential of spermidine as a vaccine adjuvant in the older adults. This phase 1, double-blinded, randomised controlled trial is designed as a feasibility study to examine the safety of Spermidine supplements and its effects on the immune response (antibodies) to COVID vaccine in older people. AIMS AND OBJECTIVES The primary objective of this feasibility study is to determine the safety of daily Spermidine supplements following vaccination for Coronavirus (SARS-CoV-2) and a booster and its effects on antibody levels in older people, using validated assays. Our secondary objective is to determine the effects of daily Spermidine supplements on the immune 'memory' response to Coronavirus vaccine and a booster in older people. We will examine if Spermidine improves the duration of the antibody-mediated immune response after the Coronavirus vaccine/booster with validated assays and then determine the molecular and immunological signature driving immunity. We will also use data collected to perform a power calculation for future larger studies. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05421546
Study type Interventional
Source University of Oxford
Contact Ghada alsaleh, PharamD.PhD
Phone 01865 227374
Email [email protected]
Status Recruiting
Phase N/A
Start date August 2022
Completion date August 2, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Active, not recruiting NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Active, not recruiting NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Active, not recruiting NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Enrolling by invitation NCT05089305 - Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection Phase 2
Recruiting NCT04357990 - Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19 N/A
Recruiting NCT04528901 - Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)
Active, not recruiting NCT04527471 - Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05041907 - Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Phase 2
Active, not recruiting NCT05022329 - COVID-19 Vaccine Boosters in Patients With CKD Phase 2/Phase 3
Not yet recruiting NCT04990466 - Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine. Phase 2/Phase 3
Recruiting NCT05323799 - The Optimising Isolation, Quarantine and Distancing Study for COVID-19 (Optimise)
Recruiting NCT04661462 - Health After Covid-19 in Tyrol